Results 221 to 230 of about 35,545 (253)
Some of the next articles are maybe not open access.
Sodium–glucose co-transporter-2 inhibitors
2022Abstract This chapter studies the use of aldosterone antagonists, also known as Mineralocorticoid Receptor Antagonists (MRAs), in chronic heart failure (CHF). Overall, the results for aldosterone blockade in CHF due to left ventricular systolic dysfunction (LVSD) — now called heart failure with reduced ejection fraction (HF-REF) — have ...
Matthew M. Y. Lee +2 more
openaire +1 more source
The unexpected benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors
New Zealand Medical Journal, 2022The sodium glucose co-transporter 2 (SGLT2) inhibitor empagliflozin is currently funded in New Zealand for management of patients with type 2 diabetes who have an HbA1c >53mmol/mol and a high cardiovascular (CV) risk. Large clinical trials now provide strong evidence that SGLT2 inhibitors decrease the risk of cardiovascular death, heart failure ...
Chok G, Chan, Ralph, Stewart
openaire +2 more sources
Sodium Glucose Co-transporter 2 Inhibitors and Heart Failure
The American Journal of Cardiology, 2019Sodium-glucose co-transporter 2 (SGLT2) receptors are primarily located in the proximal convoluted tubule of the nephron. These receptors are responsible for almost 90% to 95% of tubular reabsorption of the glucose in the nephron. In patients with diabetes mellitus, due to upregulation of SGLT2 receptors, glucose reabsorption is further increased.
Raktim K. Ghosh +8 more
openaire +5 more sources
Sodium glucose co-transporter 2 inhibitors and their nephroprotective potential
Clinical Nephrology, 2017Chronic kidney disease among patients with diabetes is on the rise. The sodium glucose co-transporters 2 inhibitors are a new class of glucose-lowering agents, which act through a novel mechanism by producing a decline in glucose reabsorption in the kidney, thereby increasing glucosuria and decreasing serum glucose levels.
Natalia G, Vallianou +2 more
openaire +2 more sources
Sodium-glucose co-transporter 2 inhibitors and Sarcopenia: A controversy that must be solved
Clinical Nutrition, 2023Diabetes mellitus is a risk factor for muscle loss and sarcopenia. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) or "gliflozins" are one of the newest anti-hyperglycemic drugs. They reduce blood glucose levels by inhibiting renal glucose reabsorption in the early proximal convoluted tubule. Various randomized trials showed that SGLT2i have cardio-
Baris Afsar, Rengin Elsurer Afsar
openaire +3 more sources
A safety update on sodium glucose co‐transporter 2 inhibitors
Diabetes, Obesity and Metabolism, 2019Sodium glucose co‐transporter 2 inhibitors (SGLT2is) are the first class of glucose lowering agent to be shown to reduce cardiovascular events. They are generally well tolerated with infrequent serious adverse events. The most frequent side effect is genital mycotic infections with candida species that are usually mild to moderate in severity, easily ...
openaire +2 more sources
Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors
Drug and Therapeutics Bulletin, 2023After initially being licensed as treatment for diabetes, the range of indications for sodium-glucose co-transporter 2 (SGLT2) inhibitors has expanded to include chronic heart failure and chronic kidney disease. This article provides an overview of some of the evidence that supports the use of SGLT2 inhibitors in the management of chronic heart failure
openaire +2 more sources
Sodium-glucose co-transporter 2 inhibitors: evidence and place in therapy
Expert Review of Endocrinology & Metabolism, 2015Type 2 diabetes effects millions of people yet remains difficult to treat with oral pharmacotherapy. Metformin is the first line recommended therapy, and current guidelines suggest individualized therapy for second line selection. Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are the newest class of agents in treating type 2 diabetes via an ...
Molly G, Minze +4 more
openaire +2 more sources
Sodium Glucose Co-Transporter 2 Inhibitors: Beyond Glucose Lowering
Current Drug Targets, 2018Diabetes is an important cause of morbidity and mortality worldwide. Management of blood glucose is critical for diabetic patients since diabetes carries a risk for many diseases and disorders. Although there are several antidiabetic agents in the markets for a long time, some of the agents have dose-limiting side effects, such as hypoglycemia and ...
Ceylan, Asli F., Ren, Sidney Y.
openaire +3 more sources
Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes
Expert Opinion on Emerging Drugs, 2013Type 2 diabetes mellitus (T2DM) is a public health challenge globally. Numerous treatments are available which can improve insulin sensitivity or stimulate its secretion including biguanides, sulphonylureas and glitazones, as well as insulin, GLP-1 agonists and DPP-IV inhibitors.
Luke D, Boyle, John P H, Wilding
openaire +2 more sources